Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
One-sentence summary: An oxytocin derivative that may not trigger adverse side effects has been generated.
Editor’s summary:
A more selective oxytocin receptor agonist
Oxytocin is clinically used to induce labor, and there is growing interest in using this peptide to treat
social disorders. However, oxytocin activates not only the oxytocin receptor but also vasopressin
receptors which can trigger adverse side effects. Muttenthaler et al. generated ligands based on
oxytocin with subtle modifications, yielding a lead compound that was more selective for the oxytocin
receptor than for the vasopressin receptors. It reduced social fear in mice and induced contractile
activity in human myometrial strips without affecting cultured cardiomyocytes. Given the crosstalk
between oxytocin, vasopressin, and their receptors, this compound is a promising therapeutic lead with
an improved safety profile and a valuable probe in identifying effects that are solely mediated by the
oxytocin receptor.
1
12
3
4
5
6
7
8
9
10
11
12
13
14
Subtle modifications to oxytocin produce ligands that retain potency and
improved selectivity across species
Markus Muttenthaler1,2*, Åsa Andersson1, Irina Vetter1,3, Rohit Menon4, Marta Busnelli5,6, Lotten
Ragnarsson1, Christian Bergmayr7, Sarah Arrowsmith8, Jennifer R. Deuis1, Han Sheng Chiu1, Nathan
J. Palpant1, Margaret O'Brien9, Terry J. Smith9, Susan Wray8, Inga Neumann4, Christian W. Gruber7,10,
Richard J. Lewis1 and Paul F. Alewood1*
1 Institute for Molecular Bioscience, The University of Queensland, 4072, Brisbane, Australia
2 Faculty of Chemistry, Institute of Biological Chemistry, University of Vienna, 1090, Vienna,
Austria
3 School of Pharmacy, The University of Queensland, 4104, Brisbane, Australia
4 Department of Behavioral and Molecular Neurobiology, Regensburg Center of Neuroscience,
University of Regensburg, 93053, Regensburg, Germany
5 CNR - Institute of Neuroscience, 20129, Milan, Italy
6 Department of Biotechnology and Translational Medicine, University of Milan, 20129, Milan,
Italy
7 Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria
8 Department of Cellular and Molecular Physiology, Harris-Wellbeing Preterm Birth Centre,
Institute of Translational Medicine, University of Liverpool, L69 3BX, Liverpool, United Kingdom
9 National Centre for Biomedical Engineering Science, National University of Ireland, H91 CF50,
Galway, Ireland
10 School of Biomedical Sciences, The University of Queensland, 4072, Brisbane, Australia
2
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
* Correspondence to:
Markus Muttenthaler Email: [email protected] Tel: +61 7 3346 2985
Email: [email protected] Tel: +43 1 4277 70512
Paul F. Alewood Email: [email protected] Tel: +61 7 3346 2982
3
36
37
38
39
ABSTRACT
Oxytocin and vasopressin mediate various physiological functions that are important for
osmoregulation, reproduction, cardiovascular function, social behavior, memory and learning through
four G protein-coupled receptors that are also implicated in high-profile disorders. Targeting these
receptors is challenging because of the difficulty in obtaining ligands that retain selectivity across
rodents and humans for translational studies. We identified a selective and more stable oxytocin
receptor (OTR) agonist by subtly modifying the pharmacophore framework of human oxytocin and
vasopressin. [Se-Se]-Oxytocin-OH displayed similar potency to oxytocin but improved selectivity for
OTR, an effect that was retained in mice. Centrally infused [Se-Se]-Oxytocin-OH potently reversed
social fear in mice, confirming that this action was mediated by OTR and not by V1a or V1b
vasopressin receptors. Additionally, [Se-Se]-Oxytocin-OH produced a more regular contraction pattern
than did oxytocin in a preclinical labor induction and augmentation model using myometrial strips from
cesarean sections. [Se-Se]-Oxytocin-OH had no activity in human cardiomyocytes, indicating a
potentially improved safety profile and therapeutic window compared to those of clinically used
oxytocin. In conclusion, [Se-Se]-Oxytocin-OH is a novel probe for validating OTR as a therapeutic
target in various biological systems and is a promising new lead for therapeutic development. Our
medicinal chemistry approach may also be applicable to other peptidergic signaling systems with
similar selectivity issues.
4
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
INTRODUCTION
Oxytocin and vasopressin (also known as arginine-vasopressin) are closely related neurohypophysial
neuropeptides that are mainly synthesized in the magnocellular and parvocellular neurons of the
hypothalamus, transported in association with neurophysins to the posterior pituitary, and released into
the systemic circulation after enzymatic cleavage in response to relevant physiological stimuli (1, 2). In
the periphery, oxytocin is involved in uterine smooth muscle contraction during parturition, milk
ejection during lactation, ejaculation, and pain (3-5), while centrally released oxytocin functions as a
neurotransmitter or neuromodulator that promotes multiple behaviors (6-8) such as maternal care (9,
10), partnership bonding (8, 11, 12), social interactions (12), and stress and anxiety responses (13-15),
as largely determined in rodents. Intranasal administration of oxytocin elicits broad behavioral effects
in humans and its therapeutic potential for psychopathologies characterized by social or emotional
dysfunctions is under clinical investigation (14, 16-21). Vasopressin increases and decreases fluid
balance and blood pressure in the periphery (22-24). Centrally, vasopressin is implicated in learning
and memory (25-27), in various social behaviors including pair bonding and aggression in rodents (6,
8, 28, 29), and in stress- and anxiety-related behaviors (28-30). The ubiquitous involvement of the
oxytocin and vasopressin signaling system in diverse physiological functions reflects its ancient origin
dating back at least 600 million years (8, 31). The oxytocin and vasopressin receptors are members of
the G protein-coupled receptor (GPCR) family (5, 32) and are attractive targets in the treatment of
various high-profile disorders including cancer, pain, autism, schizophrenia, anxiety, and reproductive
and cardiovascular disorders (5, 8, 16, 33).
In humans and rodents, oxytocin acts through one receptor (OTR) and vasopressin through three
receptors (AVPRs: vasopressor V1aR, pituitary V1bR, antidiuretic V2R). Oxytocin and vasopressin are
structurally similar nonapeptides that differ only by two amino acids at positions 3 and 8 (Fig. 1A).
Two cysteine residues in positions 1 and 6 form the cyclic part of the molecules followed by a 3-
5
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
residue amidated C-terminal tail. Their chemical similarity and the high sequence homology of the
extracellular binding domains of OTR and AVPRs (~80%) leads to substantial cross talk, with oxytocin
able to activate the AVPRs and vasopressin OTR (34, 35). Specific receptor functionality is thus not
controlled by ligand selectivity, but by cell-specific variations in receptor abundance, controlled
release, receptor oligomerization, rapid clearance and specific enzymatic degradation (36). High
oxytocin and vasopressin receptor homology and overlapping distribution constitute a major hurdle in
the development of selective receptor agonists, antagonists and therapeutic candidates (37, 38). The
identification of novel drug leads is further complicated by substantial species differences, such that
rodent and human selectivity typically do not overlap, thereby restricting clinical translation (37-39).
For example, clinically used oxytocin and vasopressin analogues including desmopressin (40, 41),
carbetocin (42) and atosiban (37, 43, 44) are receptor-subtype selective in rats but not in humans. This
difference is mainly due to rapid biodegradation, renal clearance and a limited administration window
during which they can be used clinically without side effects (40, 44, 45). Despite these limitations,
oxytocin remains the ligand of choice in the clinic to induce and progress labor (46). The lack of a
complete set of selective receptor agonists and antagonists further limits our ability to characterize the
physiological responses for each subtype receptor and their relevance in disease. We therefore
commenced a program to overcome these limitations and to produce more selective ligands for this
fundamental signaling system (31, 47-51). In this study, we demonstrated that small modifications to
the structural framework of the pharmacophore of the endogenous and pharmacologically unselective
neuropeptides could be used to tune selectivity and generate analogues with an improved selectivity
profile that was conserved across mouse and human, thereby facilitating translational studies.
6
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
RESULTS
Rationale for subtle modifications. Traditional medicinal chemistry strategies that modify single or
multiple functional groups of oxytocin and vasopressin commonly yield selectivity improvements that
are not retained across species (37, 38). Based on structural data for oxytocin (4, 48, 52-54) and earlier
studies (37, 50, 55-57), we knew that oxytocin and vasopressin binding and receptor activation are
sensitive to even minor modifications. For example, ring reduction by one sulfur atom or disulfide
bond replacement by a dicarba bridge (-CH2-CH2-) causes complete loss of activity (56). N-terminal
deamination of oxytocin analogues often leads to improved OTR activation, which has led to the
generation of the slightly more stable and hydrophobic oxytocin super-agonist deamino-Oxytocin
(dOT) and the clinically used ligands Carbetocin, Desmopressin and Atosiban. (37, 55, 57).
Furthermore, changing Gly9 to Val9 in oxytocin and vasopressin switches these agonists to antagonists.
In addition, [Gly9Val]-oxytocin not only acts as an antagonist at the hV1aR but also no longer binds to
the hV1bR and the hV2R at concentrations up to 10 M (50). For vasopressin, replacement of Gly9 by
a carboxylic acid markedly decreases its vasopressor (V1aR) and antidiuretic (V2R) activity in rats
(58). We also included replacement of the disulfide bond with a diselenide bond, which has been
described as a structurally isosteric disulfide bond mimic that can increase potency and selectivity due
to the slightly more hydrophobic character of the diselenide bond (56, 59). Moreover, the lower redox
potential of the diselenide bond correlates to higher stability in a reducing environment and can
therefore be exploited to improve peptide half-life (56, 59-61). We therefore introduced subtle
modifications to the pharmacophore framework of oxytocin and vasopressin (Table S1 and Fig. 1A) to
identify those that yield selectivity gains that are retained across species.
7
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
Peptide synthesis. Two building blocks [Boc-L-Sec(Meb)-OH and dSec(Meb)-OH] were synthesized
to generate the desired sulfur or selenium modifications (Fig. 1A & B, Table S1). To acquire Boc-L-
Sec(Meb)-OH in sufficient quantities, we optimized various protocols (62-64) to obtain 28.7 g of pure
Boc-L-Sec(Meb)-OH in only three steps (Fig. 1B, 62% overall yield in a four day procedure). We also
devised a new synthetic strategy for dSec(Meb)-OH, yielding the building block in a two-step synthesis
with an overall yield of 12% (Fig. 1B). With these building blocks in hand, all of the oxytocin and
vasopressin analogues 1-16 (Fig. 1A, Table S1) were synthesized by Boc-SPPS, folded in 0.1M
NH4HCO3 and purified by RP-HPLC (59, 65).
Functional response of novel oxytocin and vasopressin ligands.
A Fluorescent Imaging Plate Reader (FLIPR) Ca2+ mobilization assay (for OTR, V1aR, V1bR) and a
second messenger cyclic adenosine monophosphate (cAMP) assay (for V2R) showed that oxytocin
activated all four human (h) receptors. EC50 at the hV1aR and hV1bR were 10-300-fold higher than at
hOTR (EC50: hOTR≈hV2R<hV1bR<hV1aR) (Fig. 1C, Table S2). Deletion of the N-terminal amino
group (dOT) increased the ability of the ligand to activate all of the AVPRs, suggesting an improved fit
of dOT in the hydrophobic transmembrane binding pocket (47) across all four receptors. Replacement
of the disulfide bond with the isosteric, yet slightly more hydrophobic diselenide bond ([Se-Se]-OT,
d[Se-Se]-OT) was well tolerated and did not lead to marked changes in potency. In particular, d[Se-
Se]-OT showed the least change in potency and selectivity compared to oxytocin. Exchange of the C-
terminal amide to acid in oxytocin (OT-OH) resulted in weaker potency at all receptors and truncations
of the C-terminus of oxytocin (compounds 8, 9, 10) yielded less potent EC50 at all receptors with
complete loss of activity at hV2R (up to 10 µM). Compounds 6, 7, 9 and 10 all showed substantial
drops in interaction with AVPRs while retaining good potency at hOTR, thereby indicating that the C-
terminus of oxytocin is a good target for improving selectively for hOTR against the three AVPRs.
8
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
In particular, the combination of diselenide replacement and C-terminal amide to acid change yielded
[Se-Se]-OT-OH (compound 6) with an improved selectivity profile for OTR compared to oxytocin
(Fig. 1C, Table S2). [Se-Se]-OT-OH displayed low nanomolar potency (7.3 nM) and partial agonism
(Emax=52%) at hOTR, no activation of hV1aR (>10 µM), a 600-fold higher EC50 at hV1bR, and a 15-
fold higher EC50 at hV2R (109 nM). N-terminal deamination of [Se-Se]-OT-OH yielded d[Se-Se]-OT-
OH, which did not have improved potency at OTR, yet at all three AVPRs, thus having a less
interesting selectivity profile than [Se-Se]-OT-OH (Fig. 1C, Table S2). d[Se-Se]-OT-OH was also a
partial agonist at hOTR (Emax=59%) and full agonist at the AVPRs.
Subtle modifications to vasopressin also modulated potency and selectivity without however yielding a
clear lead compound (Fig. 1D, Table S2). Vasopressin activated all four receptors, including hOTR
(EC50: hV2R>hV1bR>hV1aR>hOTR). Deamination of the N-terminus (dAVP) did not affect receptor
activation and the resulting ligand had potencies similar to that of vasopressin. The disulfide to
diselenide exchange ([Se-Se]-AVP, d[Se-Se]-AVP) was well tolerated and did not substantially change
the potency or selectivity profile. Deletion of Gly9 in dAVP and dAVP-OH resulted in substantial drops
in potency at all four receptors.
Oxytocin analogues 1-7, vasopressin and dAVP were further tested using the homogeneous time-
resolved fluorescence (HTRF) inositol-1-phosphate (IP1) assay (Fig. 1E, Table S3) to allow comparison
with the downstream intracellular Ca2+ changes measured using the FLIPR assay. The HTRF-IP1 assay
correlated well with the FLIPR assay (Table S4) and the potency and selectivity trends, particularly
with lead compound [Se-Se]-OT-OH were confirmed. [Se-Se]-OT-OH had an EC50 that was only 2.6-
fold less potent than that of oxytocin and no activity at hV1aR and hV1bR at concentrations up to 10
µM (Table S3).
The Ca2+-concentration-response curves of [Se-Se]-OT-OH at hOTR, hV1aR and hV1bR
(representative curves in Fig. 2A; raw FLIPR data in Fig. S1A-B) highlight its partial agonism at
9
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
hOTR, its receptor selectivity and its weak antagonism at hV1aR (17% inhibition, IC50=132 nM) (Fig.
2A & Fig. S1C-D, Table S2). The representative cAMP-concentration-response of [Se-Se]-OT-OH at
the hV2R shows that [Se-Se]-OT-OH is a full agonist at this receptor, however not as potent as
oxytocin and vasopressin (Fig. 2B). The IP1-concentration-response curves of [Se-Se]-OT-OH at
hOTR, hV1aR and hV1bR show that the same selectivity, potency and partial agonism trend is also
observed using second messenger IP1 measurements (Fig. 2C).
Binding analysis at human OTR, V1aR, V1bR, and V2R. Binding data for the oxytocin analogues
1-7, vasopressin and dAVP were obtained in radioligand-displacement assays at all four human
receptors (Table S5). The experimental inhibition constants (Ki) correlated well with the functional data
(Table S2 & S3). [Se-Se]-OT-OH displaced the 125I-V1a antagonist at hV1aR with a Ki of 57 nM,
thereby confirming the weak antagonistic effects observed in the FLIPR assay (Fig. 2D, Table S5).
Schild regression analysis for binding mode. To confirm competitive binding of [Se-Se]-OT-OH at
hOTR, we performed a series of Schild regression experiments with oxytocin and [Se-Se]-OT-OH
against hOTR antagonist atosiban using the HTRF-IP1 assay. Increasing concentrations of atosiban
shifted the concentration-response curves of oxytocin (Fig. S2A) and [Se-Se]-OT-OH (Fig. S2B) to the
right, resulting in a linear Schild plot which is representative of competitive binding at hOTR.
Binding and functional analysis of [Se-Se]-OT-OH and d[Se-Se]-OT-OH at murine OTR, V1aR,
V1bR and V2R. [Se-Se]-OT-OH retained its functional selectivity for OTR in mice and was inactive
at mV1aR and mV1bR up to concentrations of 10 µM (Fig. 3A, Table S3, Fig. S3A). [Se-Se]-OT-OH
activated mOTR with a potency similar to that of oxytocin (Table S3) (66). [Se-Se]-OT-OH activated
10
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
mV2R with an EC50 that was ~300-fold larger than that of vasopressin (67). d[Se-Se]-OT-OH also
retained its selectivity profile in mice, and was again less selective than [Se-Se]-OT-OH since it
activated all four murine receptors subtypes (Fig. S3B, Table S3). Both compounds were partial
agonists at mOTR and full agonists at mV2R. The binding data of both compounds (Table S5)
correlated well with the functional data (Table S3), including low affinity binding of [Se-Se]-OT-OH at
mV1bR fitting with absence of activation at mV1bR and binding to the mV1aR confirming mV1aR
antagonism. [Se-Se]-OT-OH displayed biphasic binding to mV1aR and mV2R (Table S5, Fig. S4A),
and d[Se-Se]-OT-OH biphasic binding to mV2R (Table S5, Fig. S4B).
Human serum stability assay. [Se-Se]-OT-OH had a ~2-fold longer half-life of 25 h compared to
oxytocin, which had a half-life of 12 h (Fig. 3B).
Human myometrial cell and strip contractility assays as proxies for induction and augmentation
of labor. To determine if the partial agonism of [Se-Se]-OT-OH and d[Se-Se]-OT-OH in the
pharmacological studies would affect their physiological activity compared to the full agonist oxytocin,
we tested the ability of compounds 1, 6 and 7 to induce contraction by activating hOTR in myometrial
cells immortalized with the human telomerase reverse transcriptase (hTERT-HM) (68) in a collagen gel
contractility assay (69, 70). Both [Se-Se]-OT-OH and d[Se-Se]-OT-OH induced a contractile response
comparable to oxytocin (Fig. S5). [Se-Se]-OT-OH and d[Se-Se]-OT-OH increased contractility by
7.4% and 9% respectively, compared to 9% for oxytocin. We then confirmed these findings in
contractility studies that used strips of human myometrium from cesarean sections. [Se-Se]-OT-OH
and oxytocin increased contraction amplitude in a concentration-dependent manner (Fig. 3C & D, Fig.
S6) and had similar potencies (Fig. S6). The contraction profile induced by [Se-Se]-OT-OH was
11
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
however more phasic and frequent compared to a more tonic-like activity induced by oxytocin at the
concentrations used (Fig. 3C & D).
Behavioral efficacy in a mouse model of social fear. [Se-Se]-OT-OH was tested in the social fear
conditioning paradigm (71) which specifically generates social fear (as measured by reduced social
investigation 24 h after fear conditioning) in mice without any confounding behavioral alterations. [Se-
Se]-OT-OH reduced social fear and facilitated social fear extinction 10 min after its
intracerebroventricular infusion compared with vehicle-treated social fear conditioned mice (Fig. 4A).
This effect was similar to that of synthetic oxytocin and of [Thr4,Gly9]-OT, a highly selective mOTR
agonist (66) that also potently reduced social fear (Fig. 4A). All unconditioned control mice treated
with either vehicle, [Se-Se]-OT-OH, oxytocin or [Thr4,Gly9]-OT showed similar extents of social
preference behavior as reflected by active exploration of conspecifics. Independently of subsequent
treatment, all social fear conditioned and unconditioned groups showed similar investigation of a non-
social stimulus (small empty cage), indicating similar amounts of non-social anxiety. During the social
fear recall (Fig. 4B), all groups of mice, irrespective of their treatment, showed high social
investigation which indicated reduced social fear and successful social fear extinction.
Maximal Ca2+ concentrations in human cardiomyocytes as a proxy for assessing cardiovascular
safety. V1aR is highly abundant in the vascular smooth muscle and heart (cardiomyocytes), and V1aR
activation has been linked to cardiovascular risks (72-76). As a proxy to assess cardiovascular risks, we
measured maximal intracellular Ca2+ concentrations in human cardiomyocytes treated with the various
ligands (Fig. 5). Vasopressin and oxytocin concentration-dependently caused an increase in maximal
intracellular Ca2+ in human cardiomyocytes with EC50 values of 121 nM and 174 nM, respectively,
which aligned well with our pharmacological results of hV1aR activation by oxytocin (Table S2 & S3). 12
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
Consistent with its improved selectivity (OTR activation without V1aR activation), [Se-Se]-OT-OH did
not affect the maximal intracellular Ca2+ concentration in cardiomyocytes up to 10 µM (Fig. 5).
DISCUSSION
Agonists and antagonists with good selectivity for the four oxytocin and vasopressin receptor subtypes
are in short supply (37, 38, 77). Physiological function and dysfunction of the receptors are therefore
studied by time- and cost-intensive knockout models, which have linked the subtypes to various
disorders including autism, schizophrenia, epilepsy, stress, aggression, depression, anxiety and pain (5,
8, 16, 33). Therapeutic development targeting these disorders has so far failed due to the challenge of
developing subtype-selective ligands that retain their selectivity across species, thereby limiting
translational studies with clinically relevant animal models (37, 38, 78).
Subtle pharmacophore framework modifications - a new strategy to retain selectivity across
murine and human receptors. This structure-activity relationship study demonstrated that subtle
modifications to the pharmacophore framework of the endogenous ligands oxytocin and vasopressin
could tune potency and selectivity, and yield ligands ([Se-Se]-OT-OH and d[Se-Se]-OT-OH) with an
improved selectivity profile that was conserved across mouse and human (Table S3, Fig. 3A). In
particular, the replacement of the disulfide bond with the diselenide bond in combination with the C-
terminal amide to acid change in oxytocin yielded [Se-Se]-OT-OH, the compound with the most
pronounced selectivity gain for OTR (Fig. 3A). Although an amide to acid modification can generally
be considered a subtle modification, it seems that either the free lone pair of the nitrogen atom is
involved in receptor recognition and activation or the negative charge of the acid contributes to activity
loss at the AVPRs. Substitution of the disulfide bond by the diselenide bond slightly increases the bond
13
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
length (+ 0.3 Å), torsion angle ( +11º) and hydrophobicity (59, 60). In particular, the change in torsion
angle could play a part in the selectivity differences observed by pushing the ligand into a left-handed
conformer, as observed in the crystal structure of dOT (54). Both modifications (diselenide bond and
C-terminal acid) had to be present to introduce the selectivity improvement.
The increased selectivity of [Se-Se]-OT-OH makes it an excellent probe to delineate OTR function in
the CNS in behavioral animal models (where V2R is not present) and a promising lead molecule for the
clinic, which we further explored in this study. We recommend that an effective concentration of 50
nM or a 10-fold higher concentration than oxytocin (in comparative studies with oxytocin) is used to
ensure OTR-mediated action while retaining OTR preference. The weak antagonism (17% inhibition of
vasopressin at hV1aR) does not affect investigation of OTR function, but needs to be taken into
account when either binding studies are carried out ([Se-Se]-OT-OH binds to hV1aR with a K i=56.8
nM) or when [Se-Se]-OT-OH is administered in presence of V1aR ligands (for example, vasopressin
can still activate the hV1aR at 83% in the presence of [Se-Se]-OT-OH). [Se-Se]-OT-OH is a partial
agonist for OTR; however, this did not affect biological function as suggested by our myometrial
contractility study, which showed that OTR activation resulted in a full response similar to that induced
by oxytocin (Fig. 3C & D, Fig. S5). Partial agonists can be beneficial in treating chronic disorders such
as pain and autism since they often do not trigger the development of adverse effects such as
overstimulation, desensitization, adaptation, tolerance and dependence as seen with full agonists.
General conclusions and guidelines for future oxytocin and vasopressin ligand design. N-terminal
deamination of oxytocin ligands improves binding and potency at all four receptors, renders oxytocin
slightly more hydrophobic and improves its stability against proteases (55). Although N-terminal
deamination of vasopressin did not affect potency and selectivity, we still recommend deamination
because it offers enhanced proteolytic stability. Considering the advancements in the area of disulfide
14
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
mimetics we recommend replacement of the disulfide bond by a non-reducible and therefore
metabolically more stable thio- or seleno-ether bond (4, 56). Modification of the C-terminus of
oxytocin and vasopressin could yield novel antagonists, considering this study and the replacement of
Gly9 in oxytocin and vasopressin by Val which resulted in an agonist to antagonist switch at the hV1aR
for both ligands (50). The FLIPR is a valuable instrument for primary screening of compounds that
target oxytocin and vasopressin receptors since it rapidly provides agonist and antagonist information
with high-throughput capabilities. Follow-up characterization of selected leads by ligand binding,
second messenger quantification and arrestin recruitment can then be used to better understand ligand
kinetics and secondary messenger signaling pathways. The structure-activity relationship study
presented here assessed affinity and functional data (FLIPR and IP1) of the most commonly used
control compounds oxytocin, vasopressin, dOT and dAVP over all four receptor subtypes in a single
study and could be a template for future oxytocin and vasopressin ligand development.
Comparison of the FLIPR and IP1 assays
Only three discrepancies with more than 50-fold difference were detected between the FLIPR and the
IP1 assays (oxytocin and dOT at hV1bR and d[Se-Se]-OT at hV1aR; Table S4) suggesting signaling
bias for these ligands at these receptors. The characteristic Ca2+ transients elicited by activation of Gq-
coupled GPCRs such as OTR, V1aR and V1bR originate from production of IP3 downstream of PLC-
activation, which induces release of Ca2+ from intracellular stores through IP3 receptors, termination of
receptor signaling and subsequent uptake of increased intracellular Ca2+ into stores and the extracellular
compartment through Ca2+ ATPases (79). In addition, Ca2+ signals can be magnified or inhibited
through intracellular feedback mechanisms such as Ca2+-induced Ca2+ release, activation of downstream
effectors that modulate intracellular Ca2+ amounts, or modification of Ca2+ signals through alternate G-
proteins such as Gi, which is involved in oxytocin and vasopressin receptor signaling (5, 80). Thus,
15
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
whereas IP3 production is a requisite step for initiation of a Ca2+ signal, other factors contribute to the
magnitude and kinetics of the observed Ca2+ transients elicited by activation of GPCRs. In contrast, the
IP1 assay indirectly quantifies production of IP3 through accumulation of its breakdown product IP1. It
is plausible that the observed differences arise because of mechanistic differences that contribute to
increases in intracellular Ca2+ and accumulation of IP1. The cellular consequences of such differences
remain unclear to date, although Ca2+ signaling is a physiologically relevant consequence of GPCR
activation. The difference in signaling produced by these ligands indicates a potential signaling bias, a
phenomenon that has been previously studied for this receptor class (43, 80-82).
[Se-Se]-OT-OH modulating central actions: Reversal of social fear. Oxytocin is linked to multiple
CNS disorders such as autism, bipolar disorders, schizophrenia, pain, anxiety and depression (5, 8, 16,
33). Studies showing that intranasal oxytocin administration can modulate social behavior in humans
has resulted in increased interest and clinical trials exploring the therapeutic potential of intranasal
oxytocin for these disorders. The exact target pharmacology and underlying mechanisms of action are
however still under debate since oxytocin also can signal through V1aR and V1bR (Table S2-S5).
Hence, receptor subtype-specific probes are critical because of the partly opposing behavioral effects of
oxytocin and vasopressin, especially in the context of anxiety and stress regulation (14). [Se-Se]-OT-
OH allows for a clear and simple distinction between the involvement of OTR compared to V1aR and
V1bR in the CNS without the use of time and cost intensive knock-out models or co-application of
species selective V1a and V1bR antagonists. This is particularly valuable for therapeutic target
validation and future drug development. In this study, we chose to behaviorally test our novel probe in
the social fear conditioning mouse model, which has clinical implication to treat social anxiety
disorders (15, 71, 83), and to compare it to the commonly used mOTR-selective agonist [Thr4,Gly7]-OT
(TGOT), which does not retain its selectivity profile for human receptors. The use of [Se-Se]-OT-OH
16
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
confirmed that this action is mediated through OTR and not through V1aR nor V1bR, and [Se-Se]-OT-
OH displayed similar effects as [Thr4,Gly7]-OT (Fig. 4A & B).
[Se-Se]-OT-OH modulating peripheral action: Labor induction and augmentation. Selectivity
against V1aR to reduce cardiovascular side effects is of particular importance for peripheral
applications since V1aR is the primary receptor subtype in the vascular smooth muscle and heart (72-
76). Clinically, oxytocin is administered intravenously to induce labor, augment weak contractions in
labor and treat postpartum hemorrhage, and intranasally to elicit lactation. Due to its activation of
AVPRs, oxytocin administration has only a limited therapeutic window of use and adverse effects
reported in the mother include anaphylactic reaction, postpartum hemorrhage, cardiac arrhythmia, fatal
afibrinogenemia, pelvic hematoma, subarachnoid hemorrhage, hypertensive episodes, rupture of the
uterus, convulsions, coma and death due to water intoxication. In the neonate, adverse effects reported
include bradycardia, cardiac arrhythmia, jaundice, retinal hemorrhage, permanent CNS or brain
damage, seizures and death (46, 84, 85). Hence, lack of AVPR activation in OTR agonists is needed to
diminish side effects.
[Se-Se]-OT-OH may be such a candidate because it only minimally raised intracellular Ca2+
concentrations in human cardiomyocytes, in contrast to oxytocin, which displayed nanomolar activity
(Fig. 5). V1aR is highly abundant in human cardiomyocytes where it mediates many of its
cardiovascular side effects. Furthermore, [Se-Se]-OT-OH and oxytocin were equipotent in augmenting
contractility in human myometrial preparations, although [Se-Se]-OT-OH displayed a more regular
contraction pattern (Fig. 3D). By contrast, oxytocin reduced contraction frequency in a concentration
dependent fashion but increased the contraction duration resulting in much greater total contractile
activity (Fig. 3C), which can lead to uterine hyperstimulation and rupture, which are life-threatening
events for mother and fetus (86, 87). [Se-Se]-OT-OH’s inactivity at V1aR, a receptor that is also
17
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
abundant in the myometrium during pregnancy and is involved in contraction (88, 89), in combination
with its partial agonism at OTR, resulted in an improved contractility profile, suggesting it would be a
more controlled and safer alternative to oxytocin to induce and augment human labor. [Se-Se]-OT-OH
thus not only reduced AVPR-related side effects but also offered additional advantages to aid labor
induction and progression through a more regular increase of contraction strength without the risk of
uterine hyperstimulation or rupture.
Human serum stability of [Se-Se]-OT-OH. Enzymatic stability is a key characteristic for many
peptide drug candidates, and hence it was important to characterize the stability of [Se-Se]-OT-OH
compared to oxytocin. Diselenide bonds exhibit a lower redox potential than disulfide bonds, rendering
such mimetics more difficult to reduce, a feature that can be exploited in improving the half-life of
peptide drug candidates (4, 56, 59-61). Peptides with C-terminal amides on the other hand are more
stable than peptides with C-terminal acids. The improved stability of [Se-Se]-OT-OH in human serum
(Fig. 3B) suggests that the impact of the more redox stable diselenide bond outweighs the disadvantage
of the C-terminal acid modification. However, the experimentally determined in vitro human serum
half-life (which was in hours) of oxytocin and [Se-Se]-OT-OH does not reflect physiologically relevant
in vivo half-life (which is in minutes) as it does not take renal clearance into account. Nonetheless, it
can assess even small stability improvements, which could be important for treating CNS disorders
through delivery methods (such as treatment of autism in children or migraines in adults (21)) that are
not affected by renal clearance.
In conclusion, we showed that subtle modifications to the pharmacophore framework of oxytocin can
lead to enhanced selectivity profiles that are conserved across species (mouse and human), thereby
overcoming a substantial hurdle in ligand development. This proof-of-concept study provides a 18
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
framework that could be applied to similar complex peptidergic signaling systems. The lead ligand
derived from this study, [Se-Se]-OT-OH, is a valuable probe that can effectively delineate the
physiological responses of OTR and is particularly suited for use in animal behavior studies looking at
the central roles of OTR. Its functional selectivity and close structural similarity to oxytocin are
important features that will help to clarify the contributions of the oxytocin and OTR signaling system
in health and disease. The improved selectivity, stability and safety profile of [Se-Se]-OT-OH could
lead to superior alternatives to oxytocin in the clinic for peripheral indications such as labor induction
and progression, and postpartum hemorrhage, as well as for central indications such as autism,
migraine, schizophrenia, anxiety and stress, where clinical trials have shown that intranasal
administered oxytocin is safe and therapeutically effective (20, 21, 90-93). [Se-Se]-OT-OH has the
potential to advance our understanding of the OTR as a therapeutic target in different animal models
and represents a promising lead molecule for various high-profile OTR-related indications.
19
388
389
390
391
392
393
394
395
396
397
398
399
MATERIALS AND METHODS
Selenocysteine building block synthesis. An optimized protocol with yield-improving modifications
was developed based on Chocat et al. (62), Tanaka et al. (63) and Oikawa et al. (64) enabling the
synthesis of the Boc-L-Sec(Meb)-OH at a scale of 20 g with an overall yield of 62%. A new two-step
strategy was devised for the synthesis of dSec(Meb)-OH with an overall yield of 12% (Fig. 1B).
Peptide synthesis. Peptides 1-16 were assembled manually by Boc-SPPS using the HBTU-mediated in
situ neutralization protocol (59, 65). The analogues were cleaved with hydrogen fluoride (94), purified
by RP-HPLC, folded over 24 h in 0.1M NH4HCO3 buffer at pH 8.2 (1 mg/10 mL, ~100 µM) and
purified by RP-HPLC to >95% purity. Peptide concentrations were determined based on peak area
detected at 214 nm by analytical RP-HPLC against oxytocin, vasopressin as standards with known
peptide content established by amino acid analysis. Using Beer-Lambert Law, the peptide
concentrations were calculated based on absorptions of standards and samples using calculated
extinction coefficients (95-97).
Transfection and membrane preparation for FLIPR, HTRF-IP1 and radioligand displacement
assays for the human receptors. hOTR, hV1aR, hV1bR and hV2R cDNA were obtained from
Origene Technologies. [Tyrosyl-2,6-3H]-oxytocin (3H-OT); 46.3 Ci/mmol, [Phenylalanyl-3,4,5-3H(N)]-
AVP (3H-AVP); 2200 Ci/mmol, 125I-linear vasopressin hV1aR antagonist ([125I]phenylacetyl-D-
Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-Tyr-NH2); 2200 Ci/mmol, FlashBLUE GPCR scintillating beads,
TopSeal-A 96-well sealing film and 384-well white optiplates were from PerkinElmer Life Sciences.
The HTRF-IP1 assay kit was from CisBio International.
COS-1 cells grown in Dulbecco’s modified Eagle’s medium and 5% fetal bovine serum in 150 mm
plates were transiently transfected with plasmid DNA (14.5 µg) encoding the human OT, V1a, V1b or
V2 receptor using Lipofectamine-2000 (29 µL; Invitrogen). The cells were harvested 48 h post
transfection and homogenized using an Ultra turrax homogenizer (22,000 rpm) in assay buffer (50 mM 20
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
Tris-HCl, 10 mM MgCl2 (5 mM MgCl2 for oxytocin), 0.1% BSA, pH 7.4) with complete protease
inhibitor cocktail (Roche Diagnostics). The homogenate was centrifuged at 484 g (2,000 rpm) for 10
min and the resulting supernatant was centrifuged at 23,665 g (14,000 rpm) for 30 min. The pellet was
re-suspended in appropriate buffer without protease inhibitor containing 10% glycerol and stored at –
80º C until assayed.
FLIPR assay for the human OTR, V1aR and V1bR. COS-1 cells transfected with hOTR, hV1aR or
hV1bR were plated 24 h prior to the experiment at a density of 35,000–50,000 cells/well on black-
walled 96-well imaging plates (Corning). Cells were loaded for 30 min at 37 °C with Fluo-4-AM (4.8
µM) in physiological salt solution (PSS; composition NaCl 140 mM, glucose 11.5 mM, KCl 5.9 mM,
MgCl2 1.4 mM, NaH2PO4 1.2 mM, NaHCO3 5 mM, CaCl2 1.8 mM, HEPES 10 mM) containing 0.3%
fatty-acid-free BSA. To allow for complete dye de-esterification, cells were washed 5-10 min with PSS
before transfer to a FLIPRTETRA (Molecular Devices) fluorescent plate reader. Ca2+ responses were
measured using a cooled CCD camera with excitation at 470–495 nM and emission at 515–575 nM.
The baseline fluorescence was set to a minimum of 1,000 arbitrary fluorescence units by adjusting
camera gain and excitation intensity. Compounds were added as 3x concentrated stock solutions in
PSS, with 10 baseline fluorescence readings prior to compound addition followed by fluorescence
reading every second for 180 seconds.
Raw fluorescence data was converted to ΔF/F values by subtracting baseline fluorescence readings
from subsequent time points and dividing by baseline fluorescence values, as previously described
(98). For concentration-response curves, maximum ΔF/F values after addition of compounds were
plotted against agonist concentration and normalized to the response elicited by the native ligand
(oxytocin for hOTR and vasopressin for hV1aR and hV1bR). A 4-parameter Hill equation with Hill
coefficient = 1 was fitted to the data using GraphPad Prism (Version 4.00).
21
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
cAMP assay for hV2R. The cDNA plasmid clones for hV2R were a gift from Ralf Schülein (FMP,
Berlin). The hV2R sequence was inserted into pKaede-MN1 (MBL) using EcoRI and HindIII
restriction sites to yield the wild type receptor. The conditions for the propagation of HEK293 cells,
creation of stably transfected cell lines were similar as described previously (48, 99). Briefly, cells were
transfected with CaPO4 transfection and 1,8x106 of HEK293 cells per 10 cm dish were prepared. 20 µL
DNA, with a concentration of 1 µg/µL, were mixed with 480 µL H2O + CaCl2 (430 µL H2O + 50 µL
CaCl2) and added to 500 µL of HEPES-buffered saline solution. After 6 min, the solution was added to
the DMEM high glucose medium (PAA), supplemented with L-glutamine and gentamicin, and the cells
were incubated for 4 h at 37 °C. After a glycerol-shock, DMEM medium was added again and the cells
were put back at 37 °C. In the following days, selection through the antibiotic Geneticin (geneticin
G418-BC liquid – 50 mg/mL (Biochrom) took place.
Cells were grown in 6-well plates. The adenine nucleotide pool was metabolically labeled by
incubating confluent monolayers for 16 h with 3H-adenine (1 μCi/well) ([2,8-3H]-adenine; 27.2
Ci/mmol, PerkinElmer Life Sciences) as described earlier (100). After preincubation, fresh medium
was added that contained 100 μM RO201724 (a cell-permeable, selective inhibitor of cAMP-specific
phosphodiesterase; Calbiochem). After 4 h, cAMP formation was stimulated by the hV2R agonist
vasopressin (50 pM – 1 μM), oxytocin (60 pM – 1 μM), synthetic oxytocin analogues (700 pM – 10
μM) or forskolin (30 μM; a cell-permeable diterpenoid that possesses anti-hypertensive, positive
inotropic, and adenylyl cyclase activating properties; Sigma-Aldrich) for 20 min at 37 °C. Assays were
performed at least 3 separate experiments in triplicate. The formation of 3H-cAMP was determined
according to Bergmayr et al. (100). Potency (EC50) and efficacy (Emax) were calculated by fitting the
data to a three-parameter logistic equation (Hill equation) using a Levenberg-Marquardt algorithm.
EC50 values were presented as mean ± SEM.
22
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
HTRF-IP1 assay for the human receptors. COS-1 cells were transiently transfected with plasmid
DNA encoding the human OTR, V1aR or V1bR using Lipofectamine-2000/DNA ratio of 2 in
Dulbecco’s modified Eagle’s medium. Assays measuring IP1 accumulation were performed 48 h after
transfection according to manufacturer’s protocol. Briefly, cells were incubated with increasing
concentration of oxytocin and vasopressin analogues (10 pM to 10 µM) in stimulation buffer
containing LiCl for 1 h in 37 C, 5% CO2 in white 384-well Optiplates. Cells were lysed by the addition
of the HTRF reagents, the europium cryptate-labeled anti-IP1 antibody and the d2-labeled IP1 analogue,
diluted in lysis buffer. The assays were incubated for 1 h at room temperature. The emission signals at
590 nm and 665 nm were measured after excitation at 340 nm using the Envision multilabel plate
reader (PerkinElmer Life Sciences). Signal was presented as the HTRF ratio: F=[(fluorescence-
665nm/fluorescence-590nm) x 104]. For concentration-response curves, the HTRF ratio values after
addition of compounds were plotted against the ligand concentration and normalized to the response
elicited without ligand (the negative control). Sigmoidal curves for the calculation of the half-maximal
excitatory concentration (EC50) values were fitted to individual data points by non-linear regression
with Hill coefficient = 1, using the software package Prism (GraphPad Software).
Radioligand displacement assay for the human receptors. Competitive binding assays were
performed using FlashBLUE GPCR scintillation beads (PerkinElmer) as previously described (56).
Reactions containing increasing concentrations of competing oxytocin and vasopressin analogues (10
pM to 10 µM), FlashBLUE GPCR beads (100 µg for hOTR and hV1aR; 200 µg for hV1bR and
hV2R), human OT, V1a, V1b, V2 receptor membrane preparations (5 µg protein) and radioligand (3H-
OT (2 nM) for hOTR, 125I-V1a antagonist ([125I]phenylacetyl-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-
Tyr-NH2) (0.5 nM) for hV1aR, and 3H-AVP (3 nM) for hV1bR and hV2R) in assay buffer (50 mM
Tris-HCl, 10 mM MgCl2 (5 mM MgCl2 for oxytocin), 0.1% BSA, pH 7.4) were established in 96-well
white polystyrene plates with clear flat bottoms in a total reaction volume of 80 µL. Radioligand
23
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
binding was detected using a Wallac 1450 MicroBeta scintillation counter (PerkinElmer Life Sciences).
Sigmoidal curves for the calculation of the half-maximal inhibitory concentration (IC50) values were
fitted to individual data points by non-linear regression with Hill coefficient = –1, using the software
package Prism (GraphPad Software).
Radioligand displacement assay for the murine receptors. Competitive binding assays were
performed using 3H-OT and 3H-AVP (Perkin Elmer) and increasing concentration of the indicated
peptides at 30 °C on membranes prepared from HEK293 cells transfected with OTR, V1aR, V1bR or
V2R murine receptors as described previously (66). Compounds affinities (Ki) were determined by
means of competition experiments in which the unlabeled compound concentrations varied from 10 pM
to 10 µM to displace 4 nM 3H-OT for mOTR and 3H-AVP for mV1aR, mV1bR and mV2R. Ligand
binding data and Ki were analyzed by means of non-linear regression and binding-competitive fitting
using Prism version 5 (GraphPad Software).
HTRF-IP1 assay and cAMP determination for the murine receptors. IP1 and cAMP accumulation
were determined in HEK293 cells transiently transfected with DNA plasmids encoding the murine OT,
V1a, V1b or V2 murine receptors using HTRF assays (IP1 and cAMP assays, CisBio International) as
previously described (66). Sigmoidal curves for the calculation of the half-maximal effective
concentration (EC50) values were fitted by non-linear regression log(agonist) vs. response fitting, using
Prism version 5 (GraphPad Software).
Stability assays. Peptides were added to human serum and aliquots were taken and analyzed by RP-
HPLC and LCMS at 1, 2, 3, 4, 12, 24 and 48 h time points as previously described (56).
Social fear conditioning mouse model. SFC was performed as previously described (71). Sample
sizes (>4 mice) were determined based on previous studies (71, 83, 101). All experimental procedures
were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the
Government of Oberpfalz and the guidelines of the NIH. All male CD1 mice (Charles River, Sulzfeld, 24
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
Germany, 8-10 weeks of age at the start of experiments) were group-housed under standard laboratory
conditions (12/12 h light/dark cycle, lights on at 06:00, 22 °C, 60 humidity, food and water ad libitum)
in polycarbonate cages (16 x 22 x 14 cm). All experimental procedures were performed between 08:00
and 15:00 h. Surgeries were performed under isoflurane anaesthesia and extreme care was taken to
minimize animal suffering. Analysis of the SFC paradigm was performed using GraphPad Prism
version 6.0 (GraphPad Software).
On day 1 of the social fear conditioning paradigm, mice were transferred from their home cage into the
conditioning chamber; after a 30-s adaptation period, an empty cage was placed in the conditioning
chamber as a non-social stimulus that mice were allowed to investigate for 3 min, before it was
replaced by an identical cage containing an unfamiliar male conspecific (which represented the social
stimulus). SFC- mice were allowed to investigate the social stimulus for 3 min without receiving any
foot shocks, whereas SFC+ mice were given a 1-s electric foot shock (0.7 mA) each time they
investigated (sniffed) the social stimulus. Mice were returned to their home cage when no further social
contact was made for 2 min. All mice investigated the non-social (empty cage) stimulus to a similar
extent and received similar number of foot shocks (Table S6). On day 2, which consisted of social fear
extinction training, mice were exposed to 3 non-social stimuli (empty cages) in their home cage to
assess non-social investigation as a parameter of non-social fear and general anxiety-related behavior.
Mice were then exposed to 6 unfamiliar social stimuli (6 different male mice) to assess social
investigation as a parameter of social fear. Mice received single acute intracerebroventricular infusions
(35-45 s) of either vehicle (2 µL; sterile Ringer solution), oxytocin (2 µL of 250 µM; 500 pmol), [Se-
Se]-OT-OH (2 µL of 250 µM; 500 pmol) or [Thr4,Gly7]-OT (2 µL of 250 µM; 500 pmol) 10 min prior
to social fear extinction. On day 3, which assessed social fear extinction recall, mice were exposed in
their home cage to 6 different unfamiliar social stimuli to investigate whether repeated exposure to
social stimuli during extinction leads to a complete reversal of social fear.
25
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
Human myometrial cell contractility assay. Human uterine myometrial smooth muscle cells
(hTERT-HM) were cultured, collagen-gels were prepared, and the assays were performed as described
previously (48, 70). Briefly, cells were cultured in DMEM-F-12/10% FBS (Invitrogen). Collagen gels
were prepared from rat tail Type 1 collagen (Sigma Aldrich), to a final concentration of 1.5 mg/mL,
and seeded in 24-well culture dishes, with 150,000 hTERT-HM cells per well. Cells in collagen gels
were allowed to equilibrate overnight in serum free DMEM medium. The ligands of interest (1 μM
concentration) were added to the serum free media and the gels released from the sides of the wells.
10% (vol/vol) FBS was used as a positive control for contraction, and unstimulated cells as the
negative control in all experiments. Gel images were captured over time, using a FluorchemTM 8900
imager, the area (cm2) of the gels were measured using AlphaEaseFC software (Alpha Innotech
Corporation). A decrease in gel area correlated with an increase in contractility.
Tissue bath myometrial contractility assays. Biopsies of myometrium were obtained from women
undergoing term (39-40 weeks) pre-labor elective cesarean section delivery at Liverpool Women’s
Hospital, Liverpool, UK. All women gave written informed consent to participate, and the study was
approved by the North West (Liverpool East) Research Ethics Committee (Ref: 10/H1002/49) and by
the Research and Development director at Liverpool Women’s Hospital NHS Foundation Trust,
Liverpool, UK. A full thickness biopsy (~2 cm3) was cut from the upper lip of the lower uterine
incision site and placed into Hanks balanced salt solution at 4 °C (102). In the laboratory, strips of
myometrium (1 mm x 2 mm x 5 mm) were dissected and placed between a force transducer and a fixed
hook using aluminum clips. Strips were continually superfused with physiological saline solution (PSS;
154 mM NaCl, 5.6 mM KCl, 1.2 mM MgSO4, 7.8 mM glucose, 10.9 mM Hepes, 2.0 mM CaCl2, pH
7.4) maintained at 36 °C. After stable spontaneous contractions developed, the strips were exposed to
rising concentrations of oxytocin or [Se-Se]-OT-OH. Data were analyzed by measuring the amplitude
of contraction using Origin Pro 9.0 software (Origin Lab Corporation) as described previously (48,
26
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
103, 104). The effect of [Se-Se]-OT-OH or oxytocin was compared to the activity preceding the
application of the first dose and data represent the change in activity compared to spontaneous control
activity (100%). Concentration-response curves were fitted using non-linear regression to calculate
EC50 values.
Human cardiomyocyte assay. Wild-type WTC11 human induced pluripotent stem cells (hiPSCs)
were used in this study. Undifferentiated cells were maintained in mTeSR1 media (Stem Cell
Technologies). Standard cardiomyocyte directed differentiation using a monolayer platform was
performed with a modified protocol based on previous reports (105-109). The differentiation set up was
initiated by plating undifferentiated hiPSCs as single cells. The cultures were treated with 1 µM CHIR-
99021 (Cayman Chemical) for 24 h before reaching confluence. Cells were induced to differentiate
(designated day 0) by replacing the culturing media with Roswell Park Memorial Institute (RPMI)
1640 media (catalog number 11875-119, Thermo Fisher Scientific) containing 3 µM CHIR-99021, 500
µg/mL bovine serum albumin (BSA) and 213 µg/mL ascorbic acid. On day 3, media was changed to
RPMI 1640 media with BSA and ascorbic acid containing 1 µM XAV-939 (Tocris Bioscience). On day
5 media was changed to RPMI 1640 containing ascorbic acid and BSA. On day 7 the media is replaced
with RPMI 1640 containing B-27 supplement with insulin (catalog number 17504-044, Thermo Fisher
Scientific). Cells were harvested using trypsin, re-plated into a 384-well black walled imaging plate
coated with CellBIND (Sigma Aldrich) at a density of 4 × 104 cells per well and cultured for 8 days
prior to experiments. Functional activity was assessed using a high-throughput FLIPRTETRA (Molecular
Devices) fluorescent imaging plate reader assay. The growth medium was removed and replaced with
Calcium 4 No-wash dye (Molecular Devices) diluted in physiological salt solution (PSS; composition
in mM: NaCl 140, glucose 11.5, KCl 5.9, MgCl2 1.4, NaH2PO4 1.2, NaHCO3 5, CaCl2 1.8, HEPES 10;
pH 7.4) according to the manufacturer's instructions and incubated at 37 °C for 30 min. Changes in
intracellular Ca2+ amounts were measured using a cooled CCD camera (excitation 470–495 nm;
27
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
emission 515–575 nm) with reads taken every 0.4 s for 240 s after addition of compound. The
maximum intracellular Ca2+ amount was determined using ScreenWorks (Version 2.2.0.14, Molecular
Devices).
Statistical analysis
All statistical comparisons were made using GraphPad Prism software and values were expressed as
means ± SEM. Student’s t test and one-way analysis of variance (ANOVA) were used to determine
statistical significance for the human myometrial cell contractility and organ bath assays. Two-way
ANOVA was used to analyze the SFC data. P values <0.05 were considered significant.
SUPPLEMENTARY MATERIALS
Materials and Methods
Fig. S1. Representative raw FLIPR data.
Fig. S2. Schild plot analysis.
Fig. S3. Functional study of [Se-Se]-OT-OH and d[Se-Se]-OT-OH at the mOTR, mV1aR, mV1bR, and
mV2R.
Fig. S4. Binding study of [Se-Se]-OT-OH and d[Se-Se]-OT-OH at the mOTR, mV1aR, mV1bR, and
mV2R.
Fig. S5. Human myometrial cell contractility assay.
Fig. S6. Human myometrial strip contractility assay.
Table S1. Overview of the synthesized peptides including details on their modifications.
28
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
Table S2. Functional potencies for oxytocin and vasopressin analogs at the hOTR, hV1aR, hV1bR, and
hV2R.
Table S3. Functional potencies for oxytocin and vasopressin analogues at the human and murine OTR,
V1aR, V1bR, and V2R.
Table S4. Comparison of functional data from the FLIPR and HTRF-IP1 assays.
Table S5. Radioligand displacement data for oxytocin and vasopressin analogs at the human and
murine OTR, V1aR, V1bR, and V2R.
Table S6. Overview of the number of electric foot shocks per mouse.
Reference (110)
29
611
612
613
614
615
616
617
618
619
620
621
622
REFERENCES AND NOTES
1. H. Gainer, Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons.
Adv. Exp. Med. Biol. 449, 15-27 (1998).
2. R. Landgraf, I. D. Neumann, Vasopressin and oxytocin release within the brain: a dynamic
concept of multiple and variable modes of neuropeptide communication. Front.
Neuroendocrinol. 25, 150-176 (2004).
3. K. Nishimori, L. J. Young, Q. Guo, Z. Wang, T. R. Insel, M. M. Matzuk, Oxytocin is required
for nursing but is not essential for parturition or reproductive behavior. Proc. Natl. Acad. Sci.
U.S.A. 93, 11699-11704 (1996).
4. A. D. de Araujo, M. Mobli, J. Castro, A. M. Harrington, I. Vetter, Z. Dekan, M. Muttenthaler, J.
Wan, R. J. Lewis, G. F. King, S. M. Brierley, P. F. Alewood, Selenoether oxytocin analogues
have analgesic properties in a mouse model of chronic abdominal pain. Nat. Commun. 5, 3165
(2014).
5. G. Gimpl, F. Fahrenholz, The oxytocin receptor system: structure, function, and regulation.
Physiol. Rev. 81, 629-683 (2001).
6. A. H. Veenema, I. D. Neumann, Central vasopressin and oxytocin release: regulation of
complex social behaviours. Prog. Brain Res. 170, 261-276 (2008).
7. I. D. Neumann, Brain oxytocin: a key regulator of emotional and social behaviours in both
females and males. J. Neuroendocrinol. 20, 858-865 (2008).
8. Z. R. Donaldson, L. J. Young, Oxytocin, vasopressin, and the neurogenetics of sociality.
Science 322, 900-904 (2008).
9. I. D. Neumann, The advantage of social living: Brain neuropeptides mediate the beneficial
consequences of sex and motherhood. Front. Neuroendocrinol. 30, 483-496 (2009).
30
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
10. C. A. Pedersen, A. J. Prange, Jr., Induction of maternal behavior in virgin rats after
intracerebroventricular administration of oxytocin. Proc. Natl. Acad. Sci. U. S. A. 76, 6661-
6665 (1979).
11. C. S. Carter, A. J. Grippo, H. Pournajafi-Nazarloo, M. G. Ruscio, S. W. Porges, Oxytocin,
vasopressin and sociality. Prog. Brain Res. 170, 331-336 (2008).
12. M. Lukas, I. Toth, S. O. Reber, D. A. Slattery, A. H. Veenema, I. D. Neumann, The
Neuropeptide Oxytocin Facilitates Pro-Social Behavior and Prevents Social Avoidance in Rats
and Mice. Neuropsychopharmacology 36, 2159-2168 (2011).
13. D. Viviani, A. Charlet, E. van den Burg, C. Robinet, N. Hurni, M. Abatis, F. Magara, R. Stoop,
Oxytocin Selectively Gates Fear Responses Through Distinct Outputs from the Central
Amygdala. Science 333, 104-107 (2011).
14. I. D. Neumann, R. Landgraf, Balance of brain oxytocin and vasopressin: implications for
anxiety, depression, and social behaviors. Trends Neurosci. 35, 649-659 (2012).
15. I. D. Neumann, D. A. Slattery, Oxytocin in General Anxiety and Social Fear: A Translational
Approach. Biol. Psychiatry 79, 213-221 (2016).
16. A. Meyer-Lindenberg, G. Domes, P. Kirsch, M. Heinrichs, Oxytocin and vasopressin in the
human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12, 524-538
(2011).
17. P. J. Zak, A. A. Stanton, S. Ahmadi, Oxytocin increases generosity in humans. PLoS ONE 2,
e1128 (2007).
18. M. Kosfeld, M. Heinrichs, P. J. Zak, U. Fischbacher, E. Fehr, Oxytocin increases trust in
humans. Nature 435, 673-676 (2005).
19. J. G. Veening, B. Olivier, Intranasal administration of oxytocin: Behavioral and clinical effects,
a review. Neurosci. Biobehav. Rev. 37, 1445-1465 (2013).
31
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
20. D. Feifel, K. Macdonald, A. Nguyen, P. Cobb, H. Warlan, B. Galangue, A. Minassian, O.
Becker, J. Cooper, W. Perry, M. Lefebvre, J. Gonzales, A. Hadley, Adjunctive Intranasal
Oxytocin Reduces Symptoms in Schizophrenia Patients. Biol. Psychiatry 68, 678-680 (2010).
21. C. J. Yatawara, S. L. Einfeld, I. B. Hickie, T. A. Davenport, A. J. Guastella, The effect of
oxytocin nasal spray on social interaction deficits observed in young children with autism: a
randomized clinical crossover trial. Mol. Psychiatry 21, 1225-1231 (2015).
22. L. Holmes Cheryl, W. Landry Donald, T. Granton John, Science review: Vasopressin and the
cardiovascular system part 1 - receptor physiology. Crit. Care 7, 427-434 (2003).
23. L. Holmes Cheryl, W. Landry Donald, T. Granton John, Science Review: Vasopressin and the
cardiovascular system part 2 - clinical physiology. Crit. Care 8, 15-23 (2004).
24. G. I. Hatton, Emerging concepts of structure-function dynamics in adult brain: the
hypothalamo-neurohypophysial system. Progress in Neurobiology 34, 437-504 (1990).
25. R. Dantzer, G. F. Koob, R. M. Bluthe, M. Le Moal, Septal vasopressin modulates social
memory in male rats. Brain Res. 457, 143-147 (1988).
26. I. F. Bielsky, S.-B. Hu, K. L. Szegda, H. Westphal, L. J. Young, Profound Impairment in Social
Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout
Mice. Neuropsychopharmacology 29, 483-493 (2004).
27. M. Engelmann, Vasopressin in the septum: not important versus causally involved in learning
and memory - two faces of the same coin? Prog. Brain Res. 170, 389-395 (2008).
28. S. R. Wersinger, E. I. Ginns, A. M. O'Carroll, S. J. Lolait, W. S. Young, III, Vasopressin V1b
receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry 7, 975-984
(2002).
32
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
29. C. F. Ferris, R. H. Melloni, Jr., G. Koppel, K. W. Perry, R. W. Fuller, Y. Delville,
Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in
golden hamsters. J. Neurosci. 17, 4331-4340 (1997).
30. R. Landgraf, The involvement of the vasopressin system in stress-related disorders. CNS
Neurol. Disord.: Drug Targets 5, 167-179 (2006).
31. C. W. Gruber, M. Muttenthaler, Discovery of defense- and neuropeptides in social ants by
genome-mining. PLoS ONE 7, e32559 (2012).
32. C. Barberis, B. Mouillac, T. Durroux, Structural bases of vasopressin/oxytocin receptor
function. J. Endocrinol. 156, 223-229 (1998).
33. C. W. Gruber, M. Muttenthaler, M. Freissmuth, Ligand-based peptide design and combinatorial
peptide libraries to target G protein-coupled receptors. Curr. Pharm. Des. 16, 3071-3088
(2010).
34. B. Chini, B. Mouillac, M.-N. Balestre, S. Trumpp-Kallmeyer, J. Hoflack, M. Hibert, M.
Andriolo, S. Pupier, S. Jard, C. Barberis, Two aromatic residues regulate the response of the
human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 397, 201-206
(1996).
35. T. Kimura, Y. Makino, F. Saji, M. Takemura, T. Inoue, T. Kikuchi, Y. Kubota, C. Azuma, T.
Nobunaga, Y. Tokugawa, O. Tanizawa, Molecular characterization of a cloned human oxytocin
receptor. Eur. J. Endocrinol. 131, 385-390 (1994).
36. B. F. Mitchell, X. Fang, S. Wong, Oxytocin: a paracrine hormone in the regulation of
parturition? Rev. Reprod. 3, 113-122 (1998).
37. M. Manning, S. Stoev, B. Chini, T. Durroux, B. Mouillac, G. Guillon, Peptide and non-peptide
agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors:
research tools and potential therapeutic agents. Prog. Brain Res. 170, 473-512 (2008).
33
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
38. B. Chini, M. Manning, G. Guillon, Affinity and efficacy of selective agonists and antagonists
for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology. Prog. Brain
Res. 170, 513-517 (2008).
39. M. Saito, A. Tahara, T. Sugimoto, 1-desamino-8-D-arginine vasopressin (DDAVP) as an
agonist on V1b vasopressin receptor. Biochem. Pharmacol. 53, 1711-1717 (1997).
40. C. Barberis, D. Morin, T. Durroux, B. Mouillac, G. Guillon, R. Seyer, M. Hibert, E. Tribollet,
M. Manning, Molecular pharmacology of AVP and OT receptors and therapeutic potential.
Drug News Perspect. 12, 279-292 (1999).
41. G. Guillon, S. Derick, A. Pena, L. L. Cheng, S. Stoev, R. Seyer, J. L. Morgat, C. Barberis, C.
Serradeil-Le Gal, J. Wagnon, M. Manning, The discovery of novel vasopressin V1b receptor
ligands for pharmacological, functional and structural investigations. J. Neuroendocrinol. 16,
356-361 (2004).
42. G. Sweeney, A. M. Holbrook, M. Levine, M. Yip, K. Alfredsson, S. Cappi, M. Ohlin, P. Schulz,
W. Wassenaar, Pharmacokinetics of carbetocin, a long-acting oxytocin analog, in nonpregnant
women. Curr. Ther. Res. 47, 528-540 (1990).
43. A. Reversi, V. Rimoldi, T. Marrocco, P. Cassoni, G. Bussolati, M. Parenti, B. Chini, The
Oxytocin Receptor Antagonist Atosiban Inhibits Cell Growth via a "Biased Agonist"
Mechanism. J. Biol. Chem. 280, 16311-16318 (2005).
44. M. Manning, S. Stoev, L. L. Cheng, N. C. Wo, W. Y. Chan, Design of oxytocin antagonists,
which are more selective than atosiban. J. Pept. Sci. 7, 449-465 (2001).
45. S. Arrowsmith, S. Wray, Oxytocin: Its Mechanism of Action and Receptor Signalling in the
Myometrium. J. Neuroendocrinol. 26, 356-369 (2014).
46. D. A. Wing, L. Sheibani, Pharmacotherapy options for labor induction. Expert Opin.
Pharmacother. 16, 1657-1668 (2015).
34
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
47. J. Koehbach, T. Stockner, C. Bergmayr, M. Muttenthaler, C. W. Gruber, Insights into the
molecular evolution of oxytocin receptor ligand binding. Biochem. Soc. Trans. 41, 197-204
(2013).
48. J. Koehbach, M. O'Brien, M. Muttenthaler, M. Miazzo, M. Akcan, A. G. Elliott, N. L. Daly, P.
J. Harvey, S. Arrowsmith, S. Gunasekera, T. J. Smith, S. Wray, U. Goransson, P. E. Dawson, D.
J. Craik, M. Freissmuth, C. W. Gruber, Oxytocic plant cyclotides as templates for peptide G
protein-coupled receptor ligand design. Proc. Natl. Acad. Sci. U.S.A. 110, 21183-21188 (2013).
49. C. W. Gruber, J. Koehbach, M. Muttenthaler, Exploring bioactive peptides from natural sources
for oxytocin and vasopressin drug discovery. Future Med. Chem. 4, 1791-1798 (2012).
50. S. Dutertre, D. Croker, N. L. Daly, A. Andersson, M. Muttenthaler, N. G. Lumsden, D. J. Craik,
P. F. Alewood, G. Guillon, R. J. Lewis, Conopressin-T from Conus Tulipa Reveals an
Antagonist Switch in Vasopressin-like Peptides. J. Biol. Chem. 283, 7100-7108 (2008).
51. M. Busnelli, G. Kleinau, M. Muttenthaler, S. Stoev, M. Manning, L. Bibic, L. A. Howell, P. J.
McCormick, S. Di Lascio, D. Braida, M. Sala, G. E. Rovati, T. Bellini, B. Chini, Design and
Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a
Channel-Like Structure. J. Med. Chem. 59, 7152-7166 (2016).
52. J. P. Rose, C.-K. Wu, C.-D. Hsiao, E. Breslow, B.-C. Wang, Crystal structure of the
neurophysin-oxytocin complex. Nat. Struct. Biol. 3, 163-169 (1996).
53. V. J. Hruby, Implications of the x-ray structure of deamino-oxytocin to agonist/antagonist-
receptor interactions. Trends Pharmacol. Sci. 8, 336-339 (1987).
54. S. P. Wood, I. J. Tickle, A. M. Treharne, J. E. Pitts, Y. Mascarenhas, J. Y. Li, J. Husain, S.
Cooper, T. L. Blundell, V. J. Hruby, A. Buku, A. J. Fischman, H. R. Wyssbrod, Crystal
structure analysis of deamino-oxytocin: conformational flexibility and receptor binding. Science
232, 633-636 (1986).
35
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
55. V. Du Vigneaud, G. Winestock, V. V. Murti, D. B. Hope, R. D. Kimbrough, Jr., Synthesis of 1-
beta-mercantopropionic acid oxytocin (desamino-oxytocin), a highly potent analogue of
oxytocin. J. Biol. Chem. 235, PC64-PC66 (1960).
56. M. Muttenthaler, A. Andersson, A. D. de Araujo, Z. Dekan, R. J. Lewis, P. F. Alewood,
Modulating oxytocin activity and plasma stability by disulfide bond engineering. J. Med. Chem.
53, 8585-8596 (2010).
57. K. Jost, M. Lebl, F. Brtnik, CRC Handbook of Neurohypophyseal Hormone Analogs. Volume I
& II. K. Jost, M. Lebl, F. Brtnik, Eds. (CRC Press, Boca Raton, FL., 1987), pp.
58. M. Manning, A. Olma, W. Klis, A. Kolodziejczyk, E. Nawrocka, A. Misicka, J. Seto, W. H.
Sawyer, Carboxy terminus of vasopressin required for activity but not binding. Nature 308,
652-653 (1984).
59. M. Muttenthaler, S. T. Nevin, A. A. Grishin, S. T. Ngo, P. T. Choy, N. L. Daly, S.-H. Hu, C. J.
Armishaw, C.-I. A. Wang, R. J. Lewis, J. L. Martin, P. G. Noakes, D. J. Craik, D. J. Adams, P.
F. Alewood, Solving the α-conotoxin folding problem: efficient selenium-directed on-resin
generation of more potent and stable nicotinic acetylcholine receptor antagonists. J. Am. Chem.
Soc. 132, 3514-3522 (2010).
60. M. Muttenthaler, P. F. Alewood, Selenopeptide chemistry. J. Pept. Sci. 14, 1223-1239 (2008).
61. M. Muttenthaler, P. F. Alewood, in Oxidative Folding of Peptides and Proteins B. Johannes, L.
Moroder, Eds. (The Royal Society of Chemistry, Cambridge, 2008) pp. 396-418.
62. P. Chocat, N. Esaki, H. Tanaka, K. Soda, Synthesis of L-selenodjenkolate and its degradation
with methionine γ-lyase. Anal. Bioanal. Chem. 148, 485-489 (1985).
63. H. Tanaka, K. Soda, Selenocysteine. Methods Enzymol. 143, 240-243 (1987).
36
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
64. T. Oikawa, N. Esaki, H. Tanaka, K. Soda, Metalloselenonein, the selenium analogue of
metallothionein: synthesis and characterization of its complex with copper ions. Proc. Natl.
Acad. Sci. U.S.A. 88, 3057-3059 (1991).
65. M. Schnölzer, P. Alewood, A. Jones, D. Alewood, S. B. H. Kent, In situ neutralization in Boc-
chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int.
J. Pept. Protein Res. 40, 180-193 (1992).
66. M. Busnelli, E. Bulgheroni, M. Manning, G. Kleinau, B. Chini, Selective and potent agonists
and antagonists for investigating the role of mouse oxytocin receptors. J. Pharmacol. Exp. Ther.
346, 318-327 (2013).
67. A. L. Del Tredici, K. E. Vanover, A. E. Knapp, S. M. Bertozzi, N. R. Nash, E. S. Burstein, J.
Lameh, E. A. Currier, R. E. Davis, M. R. Brann, N. Mohell, R. Olsson, F. Piu, Identification of
novel selective V2 receptor non-peptide agonists. Biochem. Pharmacol. 76, 1134-1141 (2008).
68. J. Condon, S. Yin, B. Mayhew, R. A. Word, W. E. Wright, J. W. Shay, W. E. Rainey,
Telomerase immortalization of human myometrial cells. Biol. Reprod. 67, 506-514 (2002).
69. J. Fitzgibbon, J. J. Morrison, T. J. Smith, M. O'Brien, Modulation of human uterine smooth
muscle cell collagen contractility by thrombin, Y-27632, TNF-α and indomethacin. Reprod.
Biol. Endocrinol. 7 (2009).
70. A. F. Attah, M. O'Brien, J. Koehbach, M. A. Sonibare, J. O. Moody, T. J. Smith, C. W. Gruber,
Uterine contractility of plants used to facilitate childbirth in Nigerian ethnomedicine. J.
Ethnopharmacol. 143, 377-382 (2012).
71. I. Toth, I. D. Neumann, D. A. Slattery, Social Fear Conditioning: A Novel and Specific Animal
Model to Study Social Anxiety Disorder. Neuropsychopharmacology 37, 1433-1443 (2012).
72. C. Hicks, L. Ramos, T. Reekie, G. H. Misagh, R. Narlawar, M. Kassiou, I. S. McGregor, Body
temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin
37
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
and the non-peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats. Br.
J. Pharmacol. 171, 2868-2887 (2014).
73. S. R. Goldsmith, M. Gheorghiade, Vasopressin Antagonism in Heart Failure. J. Am. Coll.
Cardiol. 46, 1785-1791 (2005).
74. M. O. Maybauer, D. M. Maybauer, P. Enkhbaatar, D. L. Traber, Physiology of the vasopressin
receptors. Best Practice & Research, Clinical Anaesthesiology 22, 253-263 (2008).
75. T. A. Schweiger, M. M. Zdanowicz, Vasopressin-receptor antagonists in heart failure. Am. J.
Health-Syst. Pharm. 65, 807-817 (2008).
76. X. Li, T. O. Chan, V. Myers, I. Chowdhury, X.-Q. Zhang, J. Song, J. Zhang, J. Andrel, H.
Funakoshi, J. Robbins, W. J. Koch, T. Hyslop, J. Y. Cheung, A. M. Feldman, Controlled and
Cardiac-Restricted Overexpression of the Arginine Vasopressin V1A Receptor Causes
Reversible Left Ventricular Dysfunction Through Gαq-Mediated Cell Signaling. Circulation
124, 572-581 (2011).
77. B. Chini, M. Manning, Agonist selectivity in the oxytocin/vasopressin receptor family: new
insights and challenges. Biochem. Soc. Trans. 35, 737-741 (2007).
78. M. Manning, A. Misicka, A. Olma, K. Bankowski, S. Stoev, B. Chini, T. Durroux, B. Mouillac,
M. Corbani, G. Guillon, Oxytocin and vasopressin agonists and antagonists as research tools
and potential therapeutics. J. Neuroendocrinol. 24, 609-628 (2012).
79. D. Di Scala-Guenot, D. Mouginot, M. T. Strosser, Increase of intracellular calcium induced by
oxytocin in hypothalamic cultured astrocytes. Glia 11, 269-276 (1994).
80. M. Busnelli, A. Sauliere, M. Manning, M. Bouvier, C. Gales, B. Chini, Functional Selective
Oxytocin-derived Agonists Discriminate between Individual G Protein Family Subtypes. J.
Biol. Chem. 287, 3617-3629 (2012).
38
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
81. J. D. Urban, W. P. Clarke, M. von Zastrow, D. E. Nichols, B. Kobilka, H. Weinstein, J. A.
Javitch, B. L. Roth, A. Christopoulos, P. M. Sexton, K. J. Miller, M. Spedding, R. B. Mailman,
Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp.
Ther. 320, 1-13 (2007).
82. R. Rahmeh, M. Damian, M. Cottet, H. Orcel, C. Mendre, T. Durroux, K. S. Sharma, G. Durand,
B. Pucci, E. Trinquet, J. M. Zwier, X. Deupi, P. Bron, J.-L. Baneres, B. Mouillac, S. Granier,
Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence
spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 109, 6733-6738, S6733/6731-S6733/6711 (2012).
83. I. Zoicas, D. A. Slattery, I. D. Neumann, Brain Oxytocin in Social Fear Conditioning and Its
Extinction: Involvement of the Lateral Septum. Neuropsychopharmacology 39, 3027-3035
(2014).
84. RxList, The Internet Drug Index for Prescription Drugs and Medications
(https://www.rxlist.com/.).
85. R. A. Dyer, A. J. Butwick, B. Carvalho, Oxytocin for labour and caesarean delivery:
implications for the anaesthesiologist. Curr. Opin. Anaesthesiol. 24, 255-261 (2011).
86. J. Lipshitz, C. W. Klose, Use of tocolytic drugs to reverse oxytocin-induced uterine hypertonus
and fetal distress. Obstet. Gynecol. 66, 16S-18S (1985).
87. A. G. Cahill, B. M. Waterman, D. M. Stamilio, A. O. Odibo, J. E. Allsworth, B. Evanoff, G. A.
Macones, Higher maximum doses of oxytocin are associated with an unacceptably high risk for
uterine rupture in patients attempting vaginal birth after cesarean delivery. Am. J. Obstet.
Gynecol. 199, e32/31-e32/35 (2008).
88. M. Maggi, P. Del Carlo, G. Fantoni, S. Giannini, C. Torrisi, D. Casparis, G. Massi, M. Serio,
Human myometrium during pregnancy contains and responds to V1 vasopressin receptors as
well as oxytocin receptors. J. Clin. Endocrinol. Metab. 70, 1142-1154 (1990).
39
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
89. T. Bossmar, M. Aakerlund, G. Fantoni, J. Szamatowicz, P. Melin, M. Maggi, Receptors for and
myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy:
effects of the oxytocin antagonist atosiban. Am. J. Obstet. Gynecol. 171, 1634-1642 (1994).
90. E. Macdonald, M. R. Dadds, J. L. Brennan, K. Williams, F. Levy, A. J. Cauchi, A review of
safety, side-effects and subjective reactions to intranasal oxytocin in human research.
Psychoneuroendocrinology 36, 1114-1126 (2011).
91. A. J. Guastella, S. L. Einfeld, K. M. Gray, N. J. Rinehart, B. J. Tonge, T. J. Lambert, I. B.
Hickie, Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum
Disorders. Biol. Psychiatry 67, 692-694 (2010).
92. C. A. Pedersen, C. M. Gibson, S. W. Rau, K. Salimi, K. L. Smedley, R. L. Casey, J. Leserman,
L. F. Jarskog, D. L. Penn, Intranasal oxytocin reduces psychotic symptoms and improves
Theory of Mind and social perception in schizophrenia. Schizophr. Res. 132, 50-53 (2011).
93. C. Cacciotti-Saija, I. B. Hickie, E. M. Scott, S. L. Naismith, L. Moore, G. A. Alvares, A. J.
Guastella, R. Langdon, P. B. Ward, M. A. Redoblado Hodge, A double-blind randomized
controlled trial of oxytocin nasal spray and social cognition training for young people with early
psychosis. Schizophr. Bull. 41, 483-493 (2015).
94. M. Muttenthaler, F. Albericio, P. E. Dawson, Methods, setup and safe handling for anhydrous
hydrogen fluoride cleavage in Boc solid-phase peptide synthesis. Nat. Protoc. 10, 1067-1083
(2015).
95. A. C. Conibear, N. L. Daly, D. J. Craik, Quantification of small cyclic disulfide-rich peptides.
Biopolymers 98, 518-524 (2012).
96. M. A. Buck, T. A. Olah, C. J. Weitzmann, B. S. Cooperman, Protein estimation by the product
of integrated peak area and flow rate. Anal. Biochem. 182, 295-299 (1989).
40
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
97. F. Moffatt, P. Senkans, D. Ricketts, Approaches towards the quantitative analysis of peptides
and proteins by reversed-phase high-performance liquid chromatography in the absence of a
pure reference sample. Journal of Chromatography A 891, 235-242 (2000).
98. I. Vetter, R. J. Lewis, Characterization of endogenous calcium responses in neuronal cell lines.
Biochem. Pharmacol. 79, 908-920 (2010).
99. C. Hicks, W. Jorgensen, C. Brown, J. Fardell, J. Koehbach, C. W. Gruber, M. Kassiou, G. E.
Hunt, I. S. McGregor, The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-
binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats. J.
Neuroendocrinol. 24, 1012-1029 (2012).
100. C. Bergmayr, P. Thurner, S. Keuerleber, O. Kudlacek, C. Nanoff, M. Freissmuth, C. W. Gruber,
Recruitment of a Cytoplasmic Chaperone Relay by the A2A Adenosine Receptor. J. Biol.
Chem. 288, 28831-28844 (2013).
101. I. Toth, I. D. Neumann, D. A. Slattery, Central administration of oxytocin receptor ligands
affects cued fear extinction in rats and mice in a timepoint-dependent manner.
Psychopharmacology (Heidelberg, Germany) 223, 149-158 (2012).
102. M. J. Luckas, S. Wray, A comparison of the contractile properties of human myometrium
obtained from the upper and lower uterine segments. Bjog 107, 1309-1311 (2000).
103. S. Arrowsmith, S. Quenby, A. Weeks, T. Burdyga, S. Wray, Poor spontaneous and oxytocin-
stimulated contractility in human myometrium from postdates pregnancies. PLoS ONE 7,
e36787 (2012).
104. M. J. M. Luckas, M. J. Taggart, S. Wray, Intracellular calcium stores and agonist-induced
contractions in isolated human myometrium. Am. J. Obstet. Gynecol. 181, 468-476 (1999).
41
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
105. N. J. Palpant, P. Hofsteen, L. Pabon, H. Reinecke, C. E. Murry, Cardiac development in
zebrafish and human embryonic stem cells is inhibited by exposure to tobacco cigarettes and e-
cigarettes. PLoS ONE 10, e0126259 (2015).
106. N. J. Palpant, L. Pabon, J. S. Rabinowitz, B. K. Hadland, C. L. Stoick-Cooper, S. L. Paige, I. D.
Bernstein, R. T. Moon, C. E. Murry, Transmembrane protein 88: a Wnt regulatory protein that
specifies cardiomyocyte development. Development (Cambridge, United Kingdom) 140, 3799-
3808 (2013).
107. N. J. Palpant, L. Pabon, M. Roberts, B. Hadland, D. Jones, C. Jones, R. T. Moon, W. L. Ruzzo,
I. Bernstein, Y. Zheng, C. E. Murry, Inhibition of β-catenin signaling respecifies anterior-like
endothelium into beating human cardiomyocytes. Development 142, 3198-3209 (2015).
108. X. Lian, J. Zhang, S. M. Azarin, K. Zhu, L. B. Hazeltine, X. Bao, C. Hsiao, T. J. Kamp, S. P.
Palecek, Directed cardiomyocyte differentiation from human pluripotent stem cells by
modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162-175
(2013).
109. P. W. Burridge, E. Matsa, P. Shukla, Z. C. Lin, J. M. Churko, A. D. Ebert, F. Lan, S. Diecke, B.
Huber, N. M. Mordwinkin, J. R. Plews, O. J. Abilez, B. Cui, J. D. Gold, J. C. Wu, Chemically
defined generation of human cardiomyocytes. Nat. Methods 11, 855-860 (2014).
110. A. Oksche, G. Leder, S. Valet, M. Platzer, K. Hasse, S. Geist, G. Krause, A. Rosenthal, W.
Rosenthal, Variant amino acids in the extracellular loops of murine and human vasopressin V2
receptors account for differences in cell surface expression and ligand affinity. Mol. Endocrinol.
16, 799-813 (2002).
42
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
ACKNOWLEDGMENTS
We acknowledge Alun Jones for the help with the mass spectrometry, Andrew Mulligan for their
contribution to some of the synthetic work, Dr. Lachlan Rash for conducting the qualitative control and
concentration determination of tested analogues, and Prof. Michael Freissmuth and Dr. Bice Chini for
their continuous support.
FUNDING
This work was supported by NHMRC Project [1063803] and Program grants [1072113 & 1063803].
I.V. is supported by an ARC Future Fellowship grant [FT130101215] and R.J.L. by an NHMRC
Fellowship. M.B. is an Umberto Veronesi Foundation Postdoctoral Fellow (FUV 2017). M.M. received
funding from the European Union Seventh Framework Program (FP7/2007-2013) under Marie Curie
Actions grant agreement n°[254897] and [2013-BP-B-00109], from the Secretary of Universities and
Research of the Economy and Knowledge Department of the Government of Catalonia, from the ARC
[DE150100784], and from the European Research Council (ERC) under the European Union’s Horizon
2020 research and innovation programme grant agreement n°[714366]. C.W.G. is an ARC Future
Fellow [FT140100730] and his research is supported by the Vienna Science and Technology Fund
(WWTF) through project grant [LS13-017]. S.W. and S.A. are supported by a grant (SW) and
fellowship (SA) from the Harris-Wellbeing Centre for Preterm research.
AUTHOR CONTRIBUTIONS
M.M. designed and performed the synthesis of the peptide analogs and developed the selenocysteine
chemistry. A.A., I.V., M.B., L.R. C.B., R.J.L., C.W.G. performed the pharmacological analysis of the
analogs. J.R.D., H.S.C. and N.J.P. performed the cardiomyocyte experiments. S.A., S.W., M.O. and
43
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
T.J.S. performed the uterine strip contraction studies. R.M. and I.N. performed the behavioral in vivo
experiments. M.M. and P.F.A. directed the project and wrote the paper. All authors contributed to the
discussion, preparation of figures, and interpretation of the results.
COMPETING INTERESTS
M. M. and P. F. A. are named on a US patent (2013/0130,985) for oxytocin peptide analogs. The other
authors declare that they have no competing interests.
DATA AND MATERIALS AVAILABILITY
The human induced pluripotent stem cell line (WTC11 hiPSCs) used to generate the cardiomyocytes in
this study came from Bruce Conklin’s laboratory at UCSF (Gladstone Institute).
FIGURE LEGENDS
Fig. 1. Overview of the pharmacophore framework modifications to oxytocin and vasopressin. A
NMR structure of oxytocin, with framework residues marked in red that were the focus of this study.
The table provides an overview of all synthesized peptides with details on their modifications. U,
selenocysteine; d, deamino (N-terminus); , deletion of residue; bold, modification; P, position; term,
terminus. B Synthesis of selenocysteine building blocks for Boc-SPPS to enable sulfur to selenium
replacements. C & D Functional screen of oxytocin analogues 1-10 (C) and vasopressin analogues 11-
16 (D) at human OTR, V1aR, and V1bR using the FLIPR Ca2+ signaling assay and at human V2R by
measuring cAMP accumulation. Taller bars in graphs indicate loss of function at that particular
receptor. The last row of beige bars illustrates how modifications affected potency compared to 44
947
948
949
950951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
oxytocin at hOTR and vasopressin at the hV2R (black). E Functional screen of oxytocin analogues 1-7,
vasopressin and dAVP at the human OTR, V1aR, and V1bR as assessed by measuring second
messenger IP1 accumulation and at the hV2R as assessed by measuring second messenger cAMP
accumulation. CNS (central nervous system) and PNS (peripheral nervous system) indicate where these
receptors can be found in humans. Exact EC50 values are in Table S2 & S3.
Fig. 2. Pharmacological characterization of [Se-Se]-OT-OH at all four human oxytocin and
vasopressin receptors. A Representative concentration-Ca2+ response curves of [Se-Se]-OT-OH at the
hOTR, hV1aR and hV1bR. B Representative concentration-cAMP response curves of oxytocin,
vasopressin and [Se-Se]-OT-OH at the hV2R. C Representative concentration-IP1 response curves of
[Se-Se]-OT-OH at the hOTR, hV1aR and hV1bR. D Representative concentration-response curves for
radioligand displacement assay of [Se-Se]-OT-OH at the hOTR, hV1aR, hV1bR and hV2R. All curves
were normalized to % of response of control ligand (oxytocin for OTR and vasopressin for AVPRs).
Data in (A) to (D) are presented as means ± SEM of results obtained from at least N=3 separate
experiments, each performed in triplicate.
Fig. 3. Comparison of selectivity, stability and ability to augment myometrial strip contractions
between [Se-Se]-OT-OH and oxytocin. A Functional selectivity profile of [Se-Se]-OT-OH and OT
over all four human (h) and murine (m) oxytocin and vasopressin receptors. OTR, V1aR, and V1bR
activity was measured by IP1 accumulation. V2R activity was measured by cAMP accumulation. B
Metabolic stability of [Se-Se]-OT-OH (t1/2=25 h) compared to oxytocin (t1/2=12 h) in human serum.
Data in (A, B) is presented as means ± SEM of results obtained from at least N=3 separate experiments,
each performed in triplicate. C & D Representative contraction pattern for human myometrial strips
45
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
exposed to increasing doses of oxytocin (C) or [Se-Se]-OT-OH (D). N=5 women for [Se-Se]-OT-OH,
N=8 women for oxytocin.
Fig. 4. Social fear conditioning (SFC) mouse study. (A and B) Unconditioned (SFC-) and
conditioned (SFC+) mice were intracerebroventricularly infused with either vehicle (Ringer solution 2
µL; N=9 SFC- mice; N=10 SFC+ mice) or [Se-Se]-OT-OH (250 µM/2 µL, 500 pmol; N=7 SFC- mice;
N=7 SFC+ mice). Oxytocin (250 µM/2 µL; 500 pmol; N=10 mice) and [Thr4,Gly7]-OT (250 µM/2 µL;
500 pmol; N=4 mice) were only infused into SFC+ mice 10 min prior to extinction training. Percentage
of mice that investigated three non-social stimuli (empty cage) and six social stimuli (cage with a
conspecific) during social fear extinction (day 2; A) and six social stimuli during social fear extinction
recall (day 3; B). Data are represented as mean ± SEM. Data were analyzed using two-way ANOVA
for repeated measures. (A) #P <0.05 SFC+/Vehicle compared to SFC+/[Se-Se]-OT-OH; *P <0.05
SFC+/Vehicle compared to SFC+/OT, SFC+/[Thr4,Gly7]-OT and SFC-/Vehicle; (B) $P <0.05
SFC+/Vehicle compared to SFC+/OT and SFC-/Vehicle.
Fig. 5. Effects of vasopressin, oxytocin and [Se-Se]-OT-OH on maximal intracellular Ca2+ in
human cardiomyocytes. FLIPR assays showing the effect of vasopressin, oxytocin and [Se-Se]-OT-
OH on the maximal intracellular Ca2+ concentrations. Data are presented as mean ± SEM, N=4 wells
per data point.
46
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012